“
TL;DR
The authors genotyped 215 patients from the French SToRM cohort with metastatic breast cancer to assess the impact of the FPR1 rs867228 polymorphism on age at diagnosis.
Oncoimmunology · 7 authors, 7 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
The authors genotyped 215 patients from the French SToRM cohort with metastatic breast cancer to assess the impact of the FPR1 rs867228 polymorphism on age at diagnosis.
The authors genotyped 215 patients from the French SToRM cohort with metastatic breast cancer to assess the impact of the FPR1 rs867228 polymorphism on age at diagnosis. The variant also significantly anticipated the age at metastasis and death in the luminal B HER2-negative subgroup.